TRENDING KEYWORDS
Bristol-Myers (BMY, $65.44) gets FDA approval on gastric cancer treatment
Bristol-Myers Squibb got approval for Opdivo as a treatment for gastric cancer from the Food and Drug Administration (FDA).
Opdivo as an injection combined with chemotherapy to treat patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. FDA’s approval is based on a Phase 3 trial.
As demonstrated in the … trial, Opdivo is the first and only immunotherapy combined with chemotherapy to deliver superior overall survival versus chemotherapy alone in first-line metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma,”said Adam Lenkowsky, general manager of oncology at the company.
Earlier this week, Truist boosted rating on the pharmaceutical company’s shares to buy from hold, citing optimism about its drug pipeline. Truist hiked price target to $74 a share from $66 on the shares.
Momentum Indicator for BMY turns positive, indicating new upward trend
BMY saw its Momentum Indicator move above the 0 level on May 13, 2022. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 61 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 72%.
Current price $75.53 crossed the support line at $75.06 and is trading between $76.78 resistance and $75.06 support lines. Throughout the month of 04/12/22 - 05/13/22, the price experienced a -0.98% Downtrend. During the week of 05/06/22 - 05/13/22, the stock fell -1%.
The Stochastic Indicator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 32 of 48 cases where BMY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
Following a +2.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 226 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 187 of 301 cases where BMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
The 10-day RSI Indicator for BMY moved out of overbought territory on April 22, 2022. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 17 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 41%.
The Moving Average Convergence Divergence Histogram (MACD) for BMY turned negative on April 19, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 22 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 45%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
BMY broke above its upper Bollinger Band on April 07, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 59%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.07.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.110) is normal, around the industry mean (6.847). P/E Ratio (26.882) is within average values for comparable stocks, (85.171). Projected Growth (PEG Ratio) (2.437) is also within normal values, averaging (3.164). Dividend Yield (0.027) settles around the average of (0.026) among similar stocks. P/S Ratio (3.583) is also within normal values, averaging (3.807).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 14 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. BMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
The average market capitalization across the Pharmaceuticals: Major Industry is 77.6B. The market cap for tickers in the group ranges from 226K to 465.4B. JNJ holds the highest valuation in this group at 465.4B. The lowest valued company is NEWG at 226K.
The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -1.49%. For the same Industry, the average monthly price growth was -5.38%, and the average quarterly price growth was -8.71%. GIFOF experienced the highest price growth at 17.34%, while DCHPF experienced the biggest fall at -28.83%.
The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -5.23%. For the same stocks of the Industry, the average monthly volume growth was 12.33% and the average quarterly volume growth was -2.15%
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Stocks in the group have a Negative Outlook today, backed by the TrendWeek Indicator. Tickeron has a negative outlook on this group and predicts a further decline by more than 4.00% within the next month with a likelihood of 60%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.01.
5 stocks in the group of tickers confirmed the negative outlook based on the Aroon indicator with average odds of 59%.
The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Merck & Co (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY).
The average market capitalization across the group is 112.2B. The market cap for tickers in the group ranges from 13M to 277.1B. LLY holds the highest valuation in this group at 277.1B. The lowest valued company is YMTX at 13M.
The average weekly price growth across all stocks in the group was -1.85%. For the same group, the average monthly price growth was -9.93%, and the average quarterly price growth was -14.37%. MRK experienced the highest price growth at 2.29%, while BTX experienced the biggest fall at -14.07%.
- 5/12/22 5:38 AM: GlaxoSmithKline (GSK, $42.53) was a top loser this week, declining -5.82%
- 5/12/22 5:38 AM: Yumanity Therapeutics (YMTX, $1.04) is a top weekly loser for penny stocks, falling -21.21%
- 5/7/22 5:28 AM: Royalty Pharma (RPRX, $39.72) was a top loser this week, declining -6.72%
The average weekly volume growth across all stocks in the group was 39.66%. For the same stocks of the group, the average monthly volume growth was 34.84% and the average quarterly volume growth was 33.85%
- 3/25/22 6:03 AM: The volume for Yumanity Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 661% of the 65-Day Volume Moving Average
- 3/23/22 4:46 AM: The volume for Yumanity Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 268% of the 65-Day Volume Moving Average
- 2/18/22 6:25 AM: The volume for Yumanity Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 204% of the 65-Day Volume Moving Average
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Latest blogs by Abhoy Sarkar
Top Blogs
